• MorphoSys and Incyte sign $900m deal for B-cell malignancies drug pharmaceutical-technology
    January 15, 2020
    Germany-based MorphoSys has announced it has signed a collaboration and license agreement with the US company Incyte to continue the global development and commercialisation of the former’s tafasitamab (MOR208) for B-cell malignancies.
PharmaSources Customer Service